Lindahl was the legal advisor to Senzime AB (publ) in connection with the company’s list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market. Trading on Nasdaq Stockholm began on 30 June 2021.
Senzime develops and markets unique CE marked and FDA approved medical device solutions, driven by unique algorithms and sensors for bedside monitoring of anesthesia. Senzime’s TetraGraph is a system that measures the level of neuromuscular blockade digitally and continuously to prevent complications, improve clinical precision and simplify management of care. Senzime’s vision is a world without anesthesiarelated complications, and safe emergence from anesthesia for all patients.
Lindahl’s team consisted of Mattias Prage, Helena Lindbäck, Andreas Mellberg, Amanda Sjöberg och Erik Vikström. A number of other persons also contributed with their expertise in various parts of the project.
